Weiss Multi Strategy Advisers LLC decreased its position in shares of Viking Therapeutics Inc (NASDAQ:VKTX) by 83.1% in the fourth quarter, HoldingsChannel.com reports. The firm owned 20,000 shares of the biotechnology company’s stock after selling 98,000 shares during the quarter. Weiss Multi Strategy Advisers LLC’s holdings in Viking Therapeutics were worth $153,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Knott David M lifted its holdings in shares of Viking Therapeutics by 0.6% during the fourth quarter. Knott David M now owns 238,102 shares of the biotechnology company’s stock worth $1,821,000 after purchasing an additional 1,502 shares during the period. Bank of New York Mellon Corp lifted its holdings in shares of Viking Therapeutics by 0.4% during the fourth quarter. Bank of New York Mellon Corp now owns 387,039 shares of the biotechnology company’s stock worth $2,960,000 after purchasing an additional 1,555 shares during the period. TIAA CREF Investment Management LLC raised its position in Viking Therapeutics by 1.6% during the third quarter. TIAA CREF Investment Management LLC now owns 98,296 shares of the biotechnology company’s stock valued at $1,712,000 after acquiring an additional 1,562 shares in the last quarter. Court Place Advisors LLC raised its position in Viking Therapeutics by 18.5% during the fourth quarter. Court Place Advisors LLC now owns 12,800 shares of the biotechnology company’s stock valued at $98,000 after acquiring an additional 2,000 shares in the last quarter. Finally, Meeder Asset Management Inc. raised its position in Viking Therapeutics by 63.5% during the fourth quarter. Meeder Asset Management Inc. now owns 7,309 shares of the biotechnology company’s stock valued at $56,000 after acquiring an additional 2,839 shares in the last quarter. 65.69% of the stock is owned by hedge funds and other institutional investors.

Several research analysts recently weighed in on VKTX shares. Maxim Group reduced their price target on Viking Therapeutics from $28.00 to $20.00 and set a “buy” rating for the company in a research report on Thursday, March 14th. B. Riley started coverage on Viking Therapeutics in a research report on Tuesday, December 11th. They set a “buy” rating and a $16.00 price target for the company. Leerink Swann started coverage on Viking Therapeutics in a research report on Friday, February 22nd. They set a “market perform” rating and a $10.00 price target for the company. Svb Leerink started coverage on Viking Therapeutics in a research report on Friday, February 22nd. They set a “mkt perform” rating for the company. Finally, William Blair reiterated an “outperform” rating on shares of Viking Therapeutics in a research report on Thursday, March 14th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $22.88.

Shares of VKTX stock opened at $8.26 on Friday. Viking Therapeutics Inc has a twelve month low of $3.69 and a twelve month high of $24.00.

Viking Therapeutics (NASDAQ:VKTX) last posted its quarterly earnings data on Wednesday, March 13th. The biotechnology company reported ($0.07) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.10) by $0.03. On average, equities analysts predict that Viking Therapeutics Inc will post -0.47 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Weiss Multi Strategy Advisers LLC Decreases Position in Viking Therapeutics Inc (VKTX)” was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this piece of content can be accessed at https://www.watchlistnews.com/weiss-multi-strategy-advisers-llc-decreases-position-in-viking-therapeutics-inc-vktx/2912153.html.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures.

Featured Article: Intrinsic Value

Want to see what other hedge funds are holding VKTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Viking Therapeutics Inc (NASDAQ:VKTX).

Institutional Ownership by Quarter for Viking Therapeutics (NASDAQ:VKTX)

Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.